{"id":"W7108604932","doi":"10.1182/blood-2025-2262","title":"Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dexamethasone; Daratumumab; Clinical endpoint; Multiple myeloma; Bortezomib; Phases of clinical research; Intention-to-treat analysis; Randomized controlled trial; Randomization","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005182171,0.00107071,0.002091062,0.0002981329,0.0005357065,0.0009789389,0.0008731688,0.001040192,0.005047121],"category_scores_gemma":[0.001718735,0.0005578285,0.002109429,0.0002998201,0.0007620582,0.0008376632,0.000689037,0.003688487,0.001027366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000891241,"about_ca_system_score_gemma":0.001673951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004596677,"about_ca_topic_score_gemma":0.001620024,"domain_scores_codex":[0.9987123,0.000809526,0.00008029363,0.0001405542,0.00009358744,0.0001637684],"domain_scores_gemma":[0.9985127,0.0004270349,0.0003353641,0.0001292711,0.00007848791,0.0005172447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9717943,0.009093475,0.002581296,0.0002714439,0.001105998,0.00003856248,0.00006321523,0.000378415,0.002857503,0.00005058356,0.0009188845,0.01084636],"study_design_scores_gemma":[0.7010595,0.2801571,0.01329652,0.00004511369,0.00142762,0.0001013855,0.00005193312,0.0005734562,0.001498593,0.0002046036,0.001557546,0.00002662239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922106,0.001825944,0.0003788164,0.0002948237,0.0001356203,0.002282282,0.001634138,0.00005353023,0.001184259],"genre_scores_gemma":[0.9883129,0.000702449,0.001125574,0.0008374964,0.000275918,0.003763268,0.002583912,0.00002444361,0.002374134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005182171,"threshold_uncertainty_score":0.02740628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02657468122457003,"score_gpt":0.322453296623898,"score_spread":0.295878615399328,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}